Lynkuet (Elinzanetant) and Hormone Therapy Comparison in Menopause for Hot Flashes: A Comprehensive Guide
Menopause brings significant changes to a woman's life, with hot flashes being one of the most disruptive symptoms experienced by up to 80% of women. For decades, hormone therapy has been the gold standard treatment, but the recent FDA approval of Lynkuet (elinzanetant) in October 2025 offers women a promising new alternative. This comprehensive guide compares these treatment options to help you make informed decisions about managing your menopausal symptoms.[1][2][3][4]
Understanding Hot Flashes and Their Impact on Quality of Life
Hot flashes, also called vasomotor symptoms, are sudden feelings of intense heat accompanied by sweating, flushing, and sometimes chills. These episodes can occur during the day or night (night sweats), significantly disrupting daily activities, work productivity, sleep quality, and overall well-being.[3][5][6]
Research shows that women experiencing hot flashes report substantially lower health-related quality of life, with the most affected areas being sleep problems, concentration difficulties, mood changes, and physical exhaustion. The median duration of moderate to severe hot flashes is approximately 7.4 years, though some women experience symptoms well into their 60s and 70s.[7][8][5][6]
What is Lynkuet (Elinzanetant)? The New Menopause Drug
Lynkuet (elinzanetant) represents a breakthrough in menopausal symptom management as the first dual neurokinin receptor antagonist approved for treating moderate to severe hot flashes due to menopause. Bayer received FDA approval on October 24, 2025, making it the third nonhormonal treatment option available in the United States.[2][4]
How Lynkuet Works: Mechanism of Action
Unlike hormone therapy, which replaces declining estrogen levels, Lynkuet works by targeting specific receptors in the brain's temperature control center. The drug blocks both neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors on specialized neurons called KNDy neurons (kisspeptin/neurokinin B/dynorphin neurons) located in the hypothalamus.[4][9][10][11]
During menopause, declining estrogen causes KNDy neurons to become hyperactive, releasing excessive amounts of neurokinin B and substance P. These chemicals trigger the thermoregulatory center to initiate heat dissipation responses—cutaneous vasodilation and sweating—which manifest as hot flashes. By blocking both NK1 and NK3 receptors, elinzanetant dampens this neuronal hyperactivity and reduces vasomotor symptoms without affecting hormone levels.[10][12][11][13][1][4]
Clinical Trial Results: OASIS Studies
The FDA approval was supported by three pivotal Phase III clinical trials—OASIS 1, OASIS 2, and OASIS 3—involving 1,420 postmenopausal women aged 40 to 65 years.[14][1][3]
OASIS 1 and 2 Trials (26-week studies):
· Enrolled 796 women experiencing moderate to severe hot flashes
· Participants taking Lynkuet 120 mg daily showed significant reductions in hot flash frequency at week 4: 55.9% (OASIS 1) and 57.9% (OASIS 2) versus 31.4% and 35.7% with placebo[1][3]
· By week 12, hot flash frequency decreased by an average of 3.2 to 3.3 episodes per day compared to baseline[3][1]
· Hot flash severity also improved significantly at both week 4 and week 12[1][3]
· Rapid onset of action: improvements observed as early as week 1[15][3]
· By week 26, over 80% of participants experienced at least a 50% reduction in vasomotor symptoms[2]
OASIS 3 Trial (52-week long-term study):
· Included 628 postmenopausal women to evaluate long-term safety and efficacy
· At week 12, women taking elinzanetant experienced a 73.8% reduction in moderate to severe hot flash frequency versus 47% with placebo[16][17][14]
· Benefits were sustained throughout the entire 52-week period[17][14]
· Significant improvements in sleep disturbances and menopause-related quality of life were maintained over one year[14][17]
Dosing and Administration
Lynkuet is formulated as 60 mg soft gel capsules. The recommended dosage is:[2]
· 120 mg once daily (two 60 mg capsules)
· Take at bedtime, with or without food
· Swallow capsules whole—do not cut, crush, or chew
· Take at approximately the same time each evening[18][19][20]
For patients taking certain medications that interact with Lynkuet, healthcare providers may reduce the dose to one capsule (60 mg) daily.[18]
Hormone Therapy for Hot Flashes: The Traditional Approach
Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and is FDA-approved as first-line therapy for menopausal hot flashes. Research demonstrates that systemic estrogen, alone or combined with progestogens, reduces hot flash frequency by approximately 75% and severity by 87%.[21][8][22][23]
Types of Hormone Therapy
Systemic Hormone Therapy:
For women with an intact uterus:
· Estrogen plus progestogen therapy (EPT) is required to protect the endometrium from hyperplasia and cancer risk[24][8]
· Common regimens include conjugated equine estrogens (0.3-0.625 mg) combined with medroxyprogesterone acetate or micronized progesterone[25][24]
For women who have had a hysterectomy:
· Estrogen-alone therapy (ET) is appropriate since there is no uterus to protect[8][24]
· Options include conjugated equine estrogens (0.3-0.625 mg daily) or estradiol (0.5-1 mg oral or 0.025-0.05 mg transdermal daily)[24][25]
Routes of Administration:
· Oral tablets
· Transdermal patches or gels
· Vaginal creams, tablets, or rings (for local symptoms)[8][25][24]
Efficacy of Hormone Therapy
Clinical trials confirm that hormone therapy is highly effective for vasomotor symptoms:[22][21][7]
· Reduces hot flash frequency by 75% compared to placebo[21]
· Decreases hot flash severity by 87%[23]
· Provides relief within 2-4 weeks of starting treatment[7][21]
· Additional benefits include prevention of bone loss, reduced fracture risk, and relief from genitourinary symptoms[7][8]
Lynkuet (Elinzanetant) and Hormone Therapy Comparison: Head-to-Head Analysis
Hot Flash Frequency Reduction:
|
Treatment |
Week 4 Reduction |
Week 12 Reduction |
Long-term Data |
|
Lynkuet |
55.9-57.9%[1][26] |
~74%[16] |
Sustained through 52 weeks[14][17] |
|
Hormone Therapy |
Variable (typically 2-4 weeks for effect)[21][7] |
~75%[21][23] |
Long-term efficacy well-established[7][8] |
Both treatments demonstrate substantial efficacy for reducing hot flash frequency and severity. Hormone therapy shows slightly higher reduction rates in some studies, but elinzanetant's rapid onset (within 1 week) offers an advantage.[15][3][1]
Sleep and Quality of Life:
· Lynkuet: Significantly improved sleep disturbances (measured by PROMIS Sleep Disturbance scores) and menopause-specific quality of life throughout 52 weeks[3][14][1]
· Hormone Therapy: Also improves sleep quality and overall quality of life, with broader benefits for mood, cognition, and vaginal health[22][8][7]
Safety Profiles
Lynkuet Safety:
Common side effects (generally mild to moderate):[17][14][15]
· Headache
· Fatigue
· Dizziness
· Somnolence/drowsiness
· Abdominal pain
· Nausea
· Diarrhea
· Muscle cramps
Serious considerations:
· Elevated liver enzymes: Observed in 0.6% of elinzanetant users versus 0.4% of placebo users; all cases resolved[17][15]
· No hepatotoxicity, endometrial hyperplasia, or significant bone density changes observed[14][17]
· Central nervous system effects: May cause daytime drowsiness; caution advised when driving[19][18]
· Contraindicated in pregnancy; can cause pregnancy loss[4][18]
· Potential for seizures in individuals with seizure history[4]
Notably, Lynkuet does NOT carry a black box warning, unlike its competitor Veozah (fezolinetant), which received an FDA black box warning in December 2024 for potential liver damage.[27][28][2]
Hormone Therapy Safety:
The Women's Health Initiative (WHI) studies provide extensive safety data on hormone therapy:[29][30][31][32][33]
Benefits:
· Lower breast cancer risk with estrogen-alone therapy (23% reduction)[31][32][33]
· Reduced breast cancer mortality (40% reduction with estrogen alone)[32][33][31]
· Lower risk of hip and vertebral fractures[30][8]
· No increased mortality from all causes[30]
Risks (primarily with estrogen plus progestin in women >60 years or >10 years post-menopause):
· Increased breast cancer incidence with combined estrogen-progestin therapy after 3-5 years (approximately 1 additional case per 1,000 women per year)[31][32][30]
· Increased risk of stroke and blood clots[34][30][24]
· Elevated risk of dementia when started after age 65[30][24]
· Increased risk of endometrial cancer with unopposed estrogen in women with a uterus[24][30]
Important context: For healthy women under age 60 or within 10 years of menopause, the benefits of hormone therapy generally outweigh risks.[35][29][25][8]
Contraindications
Lynkuet Contraindications:
· Pregnancy
· Severe liver disease (relative contraindication)
· History of seizure disorders (use with caution)[18][4]
Hormone Therapy Contraindications:
· Unexplained vaginal bleeding
· History of breast cancer or other estrogen-sensitive cancers
· Active or history of blood clots (DVT/PE)
· History of stroke or heart attack
· Severe liver disease
· Blood clotting disorders (Factor V Leiden)[36][25][8][24]
Patient Selection: Who Should Use Which Treatment?
Best Candidates for Lynkuet:
· Women who cannot or prefer not to use hormone therapy
· Women with contraindications to estrogen (breast cancer history, blood clots, stroke)[37][38][2]
· Women concerned about hormonal treatments
· Those seeking rapid symptom relief (onset within 1 week)[1][3]
· Women experiencing sleep disturbances alongside hot flashes[14][1]
Best Candidates for Hormone Therapy:
· Healthy women under age 60 or within 10 years of menopause[29][25][8]
· Women with no contraindications to hormone therapy
· Those seeking comprehensive benefits including bone protection and genitourinary symptom relief[8][22]
· Women experiencing premature menopause or early ovarian insufficiency (hormone therapy recommended until at least age 51-52)[36][25][8]
Other Nonhormonal Treatment Options
Fezolinetant (Veozah)
Approved by the FDA in May 2023, Veozah is a selective NK3 receptor antagonist. While it shares similarities with Lynkuet, key differences include:[39][40][41]
· Targets only NK3 receptors (not NK1)[39][2]
· Reduces hot flash frequency by approximately 60% at 12 weeks[40][39]
· Carries an FDA black box warning for liver toxicity added in December 2024[28][2]
· Requires baseline liver function testing and monthly monitoring for the first 3 months[28]
SSRIs and SNRIs
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are used off-label for hot flashes:[42][43][44]
· Paroxetine (7.5-20 mg): FDA-approved at low dose; reduces hot flashes by 10-25% compared to placebo[44]
· Venlafaxine (37.5-150 mg): Reduces hot flash frequency by approximately 50-60%[43][42]
· Escitalopram, citalopram, desvenlafaxine: Also effective with varying degrees of symptom reduction[44]
Side effects: Weight gain, decreased libido, nausea, insomnia. Important: Paroxetine and fluoxetine should not be used with tamoxifen due to drug interactions.[45][44]
Gabapentin and Pregabalin
These anticonvulsants are effective alternatives:[46][42][43]
· Gabapentin (300-900 mg daily): Reduces hot flashes comparably to low-dose estrogen[47]
· Pregabalin (75-150 mg twice daily): Shows statistically significant improvement[45]
Side effects: Dizziness, drowsiness, gastrointestinal discomfort.[47]
Cost and Access Considerations
Lynkuet Pricing and Access:
· Expected to be available in the US starting November 2025[2][4]
· Bayer projects annual peak sales of approximately €1 billion ($1.16 billion)[2]
· Lynkuet Access Savings & Support (LASS) program: Offers assistance for eligible patients, potentially providing medication at no cost through Bayer's Patient Assistance Foundation[4][2]
· Visit Lynkuet.com for savings information
Hormone Therapy Pricing:
· Generally less expensive than newer nonhormonal options
· Many formulations are available as generics
· Typically covered by insurance plans
Other Nonhormonal Options:
· Veozah: Projected sales of $327.3 million in fiscal 2025; patient assistance programs available[2]
· Generic SSRIs/SNRIs and gabapentin: Most affordable options, widely covered by insurance
Doctor Recommendations for Menopause Treatment
Leading medical organizations provide evidence-based guidance for managing menopausal symptoms:
The Menopause Society (formerly North American Menopause Society) Recommendations:[25][35][8]
· Hormone therapy is the most effective treatment for vasomotor symptoms and should be considered first-line for appropriate candidates
· For healthy women under 60 or within 10 years of menopause, hormone therapy has a favorable benefit-risk profile
· Individualize treatment based on symptoms, medical history, and patient preferences
· Use the lowest effective dose for the shortest duration necessary, though routine discontinuation is not required
· Nonhormonal options should be offered to women with contraindications or those who prefer alternatives
International Menopause Society Guidelines:[48][36]
· Emphasize shared decision-making between patients and healthcare providers
· Support both hormonal and nonhormonal approaches based on individual circumstances
· Recommend comprehensive assessment of cardiovascular, breast cancer, and thromboembolic risks before initiating therapy
Frequently Asked Questions (FAQs)
1. Is Lynkuet (elinzanetant) approved by the FDA?
Yes, Lynkuet received FDA approval on October 24, 2025, for treating moderate to severe hot flashes due to menopause.[49][4][2]
2. How quickly does Lynkuet work for hot flashes?
Clinical trials showed improvements as early as one week after starting treatment, with maximal benefits achieved by week 4.[15][3][1]
3. Can I take Lynkuet if I have a history of breast cancer?
Yes, Lynkuet is nonhormonal and does not contain estrogen or progesterone, making it suitable for women with breast cancer history who cannot use hormone therapy.[41][37]
4. Does Lynkuet cause liver problems like Veozah?
Lynkuet does not carry a black box warning for liver toxicity. In clinical trials, only 0.6% of users experienced elevated liver enzymes, with all cases resolving. This compares favorably to Veozah, which received a black box warning in December 2024.[28][17][15][2]
5. What is the best hormonal therapy for hot flashes?
Systemic estrogen therapy, either alone (for women without a uterus) or combined with progestogen (for women with a uterus), is the most effective treatment, reducing hot flash frequency by approximately 75%.[23][21][8]
6. Is hormone therapy safe after the Women's Health Initiative study?
For healthy women under age 60 or within 10 years of menopause, hormone therapy is considered safe with a favorable benefit-risk ratio. The WHI findings showed that risks vary significantly based on age, timing of initiation, and type of hormone therapy used.[33][35][29][8]
7. How does Lynkuet compare to Veozah for treating hot flashes?
Both are neurokinin receptor antagonists, but Lynkuet blocks both NK1 and NK3 receptors while Veozah blocks only NK3. Lynkuet may have a better safety profile, as it does not carry the black box warning for liver damage that Veozah received.[27][28][2]
8. What are the most common side effects of Lynkuet?
The most common side effects are headache, fatigue, dizziness, and drowsiness, which are generally mild to moderate.[17][15][14]
9. Can I stop hormone therapy and switch to Lynkuet?
Yes, you can transition from hormone therapy to Lynkuet under medical supervision. Discuss the timing and approach with your healthcare provider to ensure smooth transition and continued symptom management.
10. How long can I safely take Lynkuet?
Clinical trials demonstrated safety and efficacy for up to 52 weeks, with over 90% of participants choosing to continue treatment in an optional two-year extension. Long-term safety data beyond two years are still being collected.[14][17]
Key Takeaways: Making the Right Choice for You
The decision between Lynkuet (elinzanetant) and hormone therapy depends on your individual health profile, preferences, and treatment goals. Both options offer significant relief from moderate to severe hot flashes, but they work through different mechanisms and carry distinct benefit-risk profiles.
Choose Lynkuet if you:
· Have contraindications to hormone therapy
· Prefer a nonhormonal approach
· Need rapid symptom relief (within 1 week)
· Have concerns about breast cancer or cardiovascular risks associated with hormones
· Experience significant sleep disturbances alongside hot flashes
Choose Hormone Therapy if you:
· Are under 60 years old or within 10 years of menopause
· Have no contraindications to estrogen therapy
· Seek comprehensive benefits including bone protection
· Have genitourinary symptoms requiring treatment
· Prefer the most extensively studied and cost-effective option
Consider Other Nonhormonal Options if:
· You have contraindications to both Lynkuet and hormone therapy
· Cost is a primary concern (generic SSRIs, gabapentin)
· You have comorbid conditions like depression or anxiety that may benefit from SSRIs
· You prefer trying established alternatives first
Professional Medical Disclaimer
This article is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always consult with your qualified healthcare provider before starting, stopping, or modifying any treatment for menopausal symptoms. Individual responses to treatments vary, and what works best for one person may not be appropriate for another. Your healthcare provider will consider your complete medical history, current health status, risk factors, and personal preferences when recommending treatment options.
The information presented reflects current knowledge as of November 2025 and is based on published clinical trials, FDA approval documents, and medical guidelines. Treatment recommendations may evolve as new research becomes available.
References
1. Drug and Device News. PMC 2015. PMC4927013.
2. Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(16):1343-1354. doi:10.1001/jama.2024.14618
3. Panay N, et al. A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists. PMC 2025.
4. Bayer's Lynkuet Enters US Market, Taking On Astellas' Veozah in Nonhormonal Menopause Treatment. Xtalks. October 27, 2025.
5. Drug Reduces Hot Flashes by 73%, Trial Finds. UVA Health News. September 15, 2025.
6. Elinzanetant for Hot Flashes in Women Taking Hormonal Therapy for Breast Cancer. Breastcancer.org. October 26, 2025.
7. NDA 219469 NDA Approval Letter. FDA. October 2025.
8. New Menopause Drug Provides Relief for Hot Flashes. AARP. September 30, 2025.
9. FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause. AJMC. October 26, 2025.
10. Sobral MVS, et al. Efficacy and safety of elinzanetant in vasomotor symptoms associated with menopause. Science Direct. 2025. doi:10.1016/j.maturitas.2025.108594
11. Pinkerton JAV, Simon JA, Joffe H, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause. JAMA Network. October 21, 2024.
12. Fezolinetant Effect on Vasomotor Symptoms Due to Menopause in Women Unsuitable for Hormone Therapy. Taylor & Francis Online. January 31, 2025.
13. Nonhormonal Treatment of Vasomotor Symptoms of Menopause. Cleveland Clinic Journal of Medicine. March 5, 2025.
14. Oral Oestrogen and Combined Oestrogen/Progestogen Therapy Versus Placebo for Hot Flushes. Cochrane Database. October 17, 2004.
15. Management of Menopausal Symptoms. JAMA Network. September 30, 2015.
16. Hormones for Menopause Are Safe, Study Finds. NPR Health. April 30, 2024.
17. Schaudig K, et al. Efficacy and Safety of Fezolinetant for Moderate-Severe Vasomotor Symptoms Associated With Menopause. BMJ. November 17, 2024.
18. Menopausal Hormone Therapy and Cancer. National Cancer Institute. September 28, 2023.
19. Harper-Harrison G, Shanahan MM. Hormone Replacement Therapy. StatPearls. October 5, 2024.
20. Nonhormone Therapies for Vasomotor Symptom Management. Cleveland Clinic Journal of Medicine. March 31, 2024.
21. Magraith K. Making Choices at Menopause. RACGP. September 23, 2024.
22. Menopause Topics: Hormone Therapy. The Menopause Society. June 4, 2025.
23. Hill DA, et al. Hormone Therapy and Other Treatments for Symptoms of Menopause. American Family Physician. November 30, 2016.
24. Stuenkel CA, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. October 31, 2015.
25. Bayer's Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval. Yahoo Finance. October 24, 2025.
26. Prague JK, et al. Neurokinin 3 Receptor Antagonism Rapidly Improves Vasomotor Symptoms. PMC. July 24, 2018.
27. Hassan F, et al. Neurokinin 1/3 Receptor Antagonists for Menopausal Women. PMC. June 8, 2023.
28. Mittelman-Smith MA, et al. Role for Kisspeptin/Neurokinin B/Dynorphin (KNDy) Neurons in Cutaneous Vasodilatation and Temperature Regulation. PNAS. November 26, 2012.
29. Pinkerton JAV, Redick DL. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms. J Clin Endocrinol Metab. October 17, 2023.
30. Gombert-Labedens M, et al. Effects of Menopause on Temperature Regulation. Taylor & Francis. April 2, 2025.
31. Panay N, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial (OASIS-3). JAMA Internal Medicine. September 7, 2025.
32. OASIS-3 Highlights Safety and Efficacy of Elinzanetant Against VMS. Contemporary OB/GYN. October 1, 2025.
33. LYNKUET® (elinzanetant) Capsules Patient Information. Bayer HealthCare. 2025.
34. Panay N, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause (OASIS-3). PubMed. September 7, 2025.
35. Lynkuet (Elinzanetant): A New Nonhormonal Treatment for Menopausal Hot Flashes. WebMD. May 30, 2022.
36. Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms. Pharmacy Times. October 22, 2025.
37. 'Tis but a Scratch: A Critical Review of the Women's Health Initiative Evidence Associating Menopausal Hormone Therapy with Breast Cancer Risk. Menopause Journal. October 17, 2023.
38. Chlebowski RT, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up. JAMA. July 27, 2020.
39. Chlebowski RT, et al. The Women's Health Initiative Randomized Trials of Menopausal Hormone Therapy and Breast Cancer. Menopause. March 31, 2023.
40. The Menopause Society: Hormone Therapy Statement. OBG Project. November 20, 2022.
41. Non-hormonal-based Treatments for Menopausal Symptoms. British Menopause Society Consensus Statement. September 2024.
42. Allameh Z, et al. Comparison of Gabapentin with Estrogen for Treatment of Hot Flashes. PMC. June 30, 2006.
43. Huang AJ, et al. Nonhormonal Treatment of Menopausal Vasomotor Symptoms. JAMA. June 30, 2025.
44. The 2025 Menopausal Hormone Therapy Guidelines. PMC. 2025.
45. Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms. PMC. September 15, 2023.
46. F.D.A. Approves New Non-hormonal Menopause Drug To Reduce Hot Flashes. Health and Me. October 27, 2025.
47. Whiteley J, et al. The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes. PMC. December 31, 2012.
48. New Pills Treatment for Menopause Without Hormones. Rockingham Women's Health. October 26, 2025.
49. Arar MA, et al. The Effect of Menopausal Symptoms on Women's Daily Life Activities. PMC. April 2, 2023.
About the Author
